Daiichi Sankyo

Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Pharmaceutical Business Review
Daiichi Sankyo
Japan
CAR-T
axicabtagene ciloleucel
relapsed or refractory diffuse large B-cell lymphoma
Flag link:
Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer
Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer
Fierce Biotech
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
HER2-positive non-small cell lung cancer
Flag link:
AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch
AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch
Fierce Pharma
AstraZeneca
Daiichi Sankyo
clinical trials
FDA
Enhertu
cancer
breast cancer
Flag link:
Antibody-drug conjugates on the march
Antibody-drug conjugates on the march
Pharmaforum
antibody-drug conjugate
AstraZeneca
Daiichi Sankyo
Enhertu
Flag link:
Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study
Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study
Endpoints
AstraZeneca
breast cancer
Daiichi Sankyo
trastuzumab deruxtecan
gastric cancer
Flag link:
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filing
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filing
Pharmaforum
FDA
AstraZeneca
Daiichi Sankyo
advanced breast cancer
Enhertu
Flag link:
Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals
Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals
BioPharma Dive
Daiichi Sankyo
AstraZeneca
FDA
drug approvals
breast cancer
trastuzumab deruxtecan
Flag link:
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
EP Vantage
breast cancer
AstraZeneca
Daiichi Sankyo
SABCS
trastuzumab deruxtecan
Flag link:
Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute
Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute
BioSpace
Seattle Genetics
Daiichi Sankyo
antibody-drug conjugate
Flag link:
Eyeing second Japanese approval, Daiichi and Exelixis announce positive pivotal for kidney drug
Eyeing second Japanese approval, Daiichi and Exelixis announce positive pivotal for kidney drug
Endpoints
Daiichi Sankyo
Exelixis
clinical trials
diabetic nephropathy
Minnebro
Flag link:
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates
Pharmaforum
Daiichi Sankyo
Seattle Genetics
breast cancer
AstraZeneca
trastuzumab deruxtecan
Herceptin
Flag link:
Daiichi sues Seattle Genetics over tech used in high-profile ADC
Daiichi sues Seattle Genetics over tech used in high-profile ADC
Fierce Biotech
Daiichi Sankyo
Seattle Genetics
antibody-drug conjugate
AstraZeneca
DS-8201
Flag link:
Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny
Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny
Fierce Pharma
Daiichi Sankyo
oncology
painkillers
opioids
opioid crisis
Flag link:
Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute
Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute
Pharmaceutical Business Review
Daiichi Sankyo
Sarah Cannon Research Institute
antibody-drug conjugate
DS-7300
clinical trials
solid tumors
Flag link:
Recent Job Cuts in the Biopharma Industry
Recent Job Cuts in the Biopharma Industry
BioSpace
Tocagen
Sanofi
Amneal
Daiichi Sankyo
Integra Life Sciences
Aclaris
Bayer
Novartis
Illumina
Merck
Roche Molecular Systems
Prometheus Labs
layoffs
Flag link:
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
Pharmaforum
Astellas
AML
Xospata
Europe
Daiichi Sankyo
Flag link:
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
Endpoints
Astellas
FDA
gilteritinib
Europe
AML
Daiichi Sankyo
Flag link:
Daiichi Sankyo to cut 69 opioid sales jobs
Daiichi Sankyo to cut 69 opioid sales jobs
Beckers Hospital Review
Daiichi Sankyo
opioids
layoffs
drug reps
Flag link:
Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions
Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions
Endpoints
Daiichi Sankyo
FDA
pexidartinib
Turalio
tenosynovial giant cell tumors
Flag link:
FDA declines to approve Daiichi Sankyo's blood cancer treatment
FDA declines to approve Daiichi Sankyo's blood cancer treatment
Reuters
Daiichi Sankyo
FDA
quizartinib
acute myeloid leukemia
Flag link:

Pages